INTRODUCTION {#sec1-1}
============

Irritable bowel syndrome (IBS) is a chronic and sometimes disabling functional bowel disorder of the gastrointestinal system,\[[@ref1]\] characterized by abdominal pain and altered bowel habit, with either predominantly diarrhea, constipation or both.\[[@ref2]\] On the basis of Rome IV criteria, IBS is divided into four subtypes based on symptoms, including IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), IBS with a mixed pattern (IBS-M) of constipation and diarrhea, and unclassified IBS (IBS-U), without any of the previous symptoms.\[[@ref3][@ref4]\]

The global prevalence of IBS is about 11%,\[[@ref5]\] with a range of 9--23%,\[[@ref6]\] and it negatively affects quality of life and work productivity. Traditionally, IBS has been conceptualized as a brain-gut disorder because of its high association with coexisting psychiatric and psychological conditions, especially anxiety and depression.\[[@ref7]\] However, the exact pathophysiology of IBS remains unclear, and the evidence for the efficacy of most drug therapies in the treatment of IBS is weak.\[[@ref8]\] This leads to unsatisfactory control of symptoms for many patients and it has been estimated that patients would give up 10 to 15 years of life expectancy for an instant cure of the disease,\[[@ref9]\] therefore, alternative approaches are needed.

Studies showing alterations in gut microbiota structure and composition have been implicated in various gastrointestinal tract disorders including IBS,\[[@ref10][@ref11]\] as symptoms of IBS often developed after an infection, known as post-infectious IBS (PI-IBS).\[[@ref12]\] Furthermore, a recent study has shown that symptom severity in IBS is negatively associated with microbial richness and a distinct microbial signature,\[[@ref13]\] and data suggest that the colonic microbiome is altered in patients with IBS when compared with healthy controls.\[[@ref14][@ref15][@ref16][@ref17]\] Probiotics are live microorganisms that have been demonstrated to exhibit potential effects on human health.\[[@ref18]\] Probiotics may influence the IBS symptoms including abdominal pain, bloating, distension, flatulence, altered bowel movements, and gut microbiota.\[[@ref19]\] Nowadays, although probiotics are used widely in clinical medicine, their efficacy and safety is not entirely clear. In the current study, we aimed to assess the efficacy and safety of probiotics in patients with IBS.

MATERIALS AND METHODS {#sec1-2}
=====================

This systematic review and meta-analysis is registered at PROSPERO, number CRD42019127391.

Inclusion criteria for study selection {#sec2-1}
--------------------------------------

### Types of studies {#sec3-1}

We included randomized controlled trials (RCTs) comparing any strain of probiotics with placebo to treat IBS and excluded case reports, case series, commentaries, quasi-RCTs, and non-randomized controlled studies.

### Inclusion criteria {#sec3-2}

\(1\) Subjects were adult patients (age \>16 years); (2) diagnosis of IBS based on either a clinician\'s opinion or meeting specific diagnostic criteria (Rome I, II, III, IV); (3) duration of treatment and follow-up at least 1 week.

### Types of interventions {#sec3-3}

As experimental intervention, any strain of probiotics or combination of probiotics with any dose was included, while the control group included patients with the same treatment besides comparative interventions.

Types of outcome measures {#sec2-2}
-------------------------

### Primary outcomes {#sec3-4}

The primary outcomes assessed were the effect on symptom relief, including relief of probiotics compared with placebo on overall IBS symptoms or abdominal pain after cessation of therapy.

### Secondary outcomes {#sec3-5}

The secondary outcomes were as follows:

Effect on overall IBS or abdominal pain symptom scores.Effect on individual IBS symptom scores including bloating, flatulence.Quality of life and adverse events.

Search methods for identification {#sec2-3}
---------------------------------

### Electronic searches {#sec3-6}

To cover as much of the relevant literature as possible, we comprehensively searched MEDLINE, CENTRAL, CINAHL, and EMBASE from inception until 1^st^ February 2019, to avoid. To avoid omitting relevant trials, without language restriction. The MEDLINE (Pubmed) search strategy was provided in [Table 1](#T1){ref-type="table"}, which will also be used in other electronic databases.

###### 

Search strategy used in Medline (via PubMed)

  No.   Search items
  ----- ------------------------------------------------
  1     irritable bowel syndrome\*
  2     irritable bowel syndrome \[mesh\]
  3     1 OR 2
  4     probiotics\*
  5     probiotics \[mesh\]
  6     4 OR 5
  7     randomized controlled trial \[pt\]
  8     controlled clinical trial \[pt\]
  9     randomized controlled trials as topic \[mesh\]
  10    animals \[mesh\] NOT humans \[mesh\]
  11    7 OR 8 OR 9 NOT 10
  12    3 AND 6 AND 11

### Search of other resources {#sec3-7}

The references of retrievable studies were manually searched. In addition, the original and references of other relevant literature, including conference proceedings, academic dissertations, reviews, systematic reviews, and meta-analysis, were also searched.

Data collection and extraction {#sec2-4}
------------------------------

### Selection of studies {#sec3-8}

Two reviewers (JR.S and CF.K) independently screened the titles, abstracts, and references from all identified reports. Potentially eligible studies were confirmed by evaluating the full text. Any disagreements were arbitrated by a third investigator (XK.Q).

### Data extraction {#sec3-9}

In order to ensure the homogeneity of the extracted data, two authors (JR.S and CF.K) independently extracted the original data in the literature onto a standardized form: the first author, year of publication, country, sample size, probiotics used (included strain and species where applicable), duration of therapy, total number of adverse events reported, criteria used to define IBS, primary or secondary outcome measure, proportion of female patients and proportion of patients according to predominant stool pattern (IBS with constipation \[IBS-C\], diarrhea \[IBS-D\], or mixed stool pattern \[IBS-M\]) were recorded. Where necessary, the author of the study was contacted to obtain the study data. Conflicts in data abstraction were resolved by a consensus, and by referring to the original article.

Risk of bias assessment {#sec2-5}
-----------------------

Two review authors (JR.S and CF.K) independently assessed the quality of the literature following the Cochrane Collaboration Handbook.\[[@ref20]\] The scoring system included the following criteria: random sequence generation, allocation concealment, blinding of participants and personnel, blinding the result assessment, incomplete data of the results, selective reporting, and other sources of bias.

Study quality was also assessed with the Jadad scale of randomized controlled trials (RCTs).\[[@ref21]\] Two review authors (JR.S and CF.K) independently assessed the quality of the included studies and discrepancies were arbitrated by a third investigator (XK.Q).

Data synthesis and statistical analysis {#sec2-6}
---------------------------------------

All included clinical studies were analyzed descriptively and summarized, Dichotomous data were expressed as a relative risk (RR), while continuous data were expressed as standardized mean difference (SMD), with 95% confidence interval (CI).

A fixed model was applied if I^2^ \<50%. Otherwise, data were pooled using a random effects model,\[[@ref22]\] to give a more conservative estimate of the range of effects of probiotics, if there was heterogeneity between studies. The heterogeneity among studies was evaluated by χ^2^ test. Where possible, the potential cause of heterogeneity was interpreted by subgroup analyses and sensitivity analyses. If there were more than 10 studies eligible, the Egger test and funnel plots were performed to detect publication bias,\[[@ref23]\] and P\< 0.10 was used to define the presence of possible publication bias. All statistical analyses were carried out using the Review Manager version 5.3 software and R software version 3.6.0.

Subgroup analysis {#sec2-7}
-----------------

Subgroup analysis was performed to determine the potential cause of heterogeneity and the effectiveness of different probiotics. Therefore, the different strains and species of probiotics were divided into subgroups for analysis.

Sensitivity analysis {#sec2-8}
--------------------

To explore the possible sources of heterogeneity, we removed each study by turn, and re-analyzed the remaining studies. The results before and after removing were compared to determine the stability of the integrative results.

RESULTS {#sec1-3}
=======

Results of the search {#sec2-9}
---------------------

Based on our search criteria, we identified 805 papers from electronic databases and other sources, of which 150 duplicate articles were excluded. The remaining 655 studies were screened through titles, abstracts, and full texts, 28 trial reports were identified for the final meta-analysis. A detailed flowchart of the selection process is shown in [Figure 1](#F1){ref-type="fig"}.

![PRISMA diagram](SJG-26-66-g001){#F1}

Study characteristics {#sec2-10}
---------------------

Twenty-eight RCTs, with a total of 3606 participants, met the inclusion criteria and were included in this review. Sample sizes ranged from 25 to 391, and the proportion of women in trials ranged between 20% and 100%. The time of treatment ranged from 4 to 24 weeks. Eighteen trials used a combination of probiotics, six Lactobacillus, two Bifidobacterium, two E. coli, one Saccharomyces. Detailed characteristics of included RCTs are provided in [Table 2](#T2){ref-type="table"}.

###### 

Characteristics of randomized controlled trials of probiotics vs. placebo in irritable bowel syndrome

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors (year)                                    Region        Sample size (% female) age range   Diagnostic criteria for IBS                                         Probiotic used and duration of therapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Measured outcomes included                                                                                                          Jadad score
  ------------------------------------------------- ------------- ---------------------------------- ------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------
  Kim *et al*.\[[@ref40]\] (2003)                   USA           25 (72)\                           RomeII,100% IBS-D                                                   Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     5
                                                                  18-75                                                                                                  One packet containing VSL\#3 (225 billion bacteria/packet) b.i.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                          Abdominal pain scores\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Bloating scores                                                                                                                     

  O'Mahony *et al*.\[[@ref50]\] (2005)              Ireland       75 (64)\                           Rome II, subtype not reported                                       Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Abdominal pain scores\                                                                                                              5
                                                                  18-75                                                                                                  Malted drink containing L. salivarius UCC4331 (1×10^10^ live bacteria/drink) or B. infantis 35624(live bacteria/drink) q.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                Bloating scores                                                                                                                     

  Kajander *et al*.\[[@ref39]\] (2005)              Finland       103 (76.7)\                        Rome I, 47.6% IBS-D, 23.3% IBS-C, 29.1% IBS-M                       Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     3
                                                                  20-65                                                                                                  One capsule containing L. rhamnosus GG,L. rhamnosus Lc705, Propionibacterium freu- denreichii, and Bifidobacterium breve Bb99 (8-9×10^9^ c.f.u./capsule) o.d. for 6 months                                                                                                                                                                                                                                                                                                                                                             Overall IBS symptom scores\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Bloating scores                                                                                                                     

  Whorwell *et al*.\[[@ref32]\] (2006)              UK            362 (100)\                         RomeII, subtype not reported                                        One capsule containing B. infantis 35624 (1×10^6^ live bacteria/capsule, 1×10^8^ live bacteria/capsule, or 1×10^10^ live bacteria/capsule) o.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                                                            Relief of overall IBS symptoms,Abdominal pain scores\                                                                               5
                                                                  18-65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Bloating scores                                                                                                                     

  Guyonnet *et al*.\[[@ref48]\] (2007)              France        267 (74.5)\                        RomeII, subtype not reported                                        Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Abdominal pain scores\                                                                                                              4
                                                                  18-65                                                                                                  Fermented milk (125 g) containing B. animalis DN173 010 (1.25×10^10^ c.f.u./125 g) S. thermophilus (1.2×10^9^ c.f.u./125 g) and L. bulgaricus (1.2×10^9^ c.f.u./125 g) b.i.d. for 6 weeks                                                                                                                                                                                                                                                                                                                                              Bloating scores\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adverse events                                                                                                                      

  Drouault-Holowacz *et al*.\[[@ref35]\] (2008)     France        106 (76)\                          Rome II, 29% IBS-D, 29% IBSC, 41% IBS-A, 1% Unclassified            One sachet containing B. longum LA 101, L. acidophilus LA 102, L. lactis LA 103, and S. thermophilus LA 104 (1×10^10^ c.f.u./sachet) o.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                                                                  Relief of overall IBS symptoms                                                                                                      5
                                                                  Unclear                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Sinn *et al*.\[[@ref31]\] (2008)                  Korea         40 (65)\                           RomeIII, 10% IBS-D, 27.5% IBS-C, 62.5%                              One capsule containing L. acidophilus SDC 2012 and 2013 (2×10^9^ c.f.u./ml) b.i.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                         Relief of overall IBS symptoms                                                                                                      5
                                                                  18-70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Zeng *et al*.\[[@ref46]\] (2008)                  China         29 (65.5)\                         RomeII, 100% IBS-D                                                  Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     4
                                                                  Unclear                                                                                                Fermented milk (200 ml) containing S. thermophilus (1×10^8^ c.f.u./ml), L. bulgaricus (1×10^7^ c.f.u./ml), L. acidophilus (1×10^7^ c.f.u./ml), and B. longum (1×10^7^ c.f.u./ml) b.i.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                    Abdominal pain scores\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Bloating scores                                                                                                                     

  Enck *et al*.\[[@ref45]\] (2009)                  Germany       298 (49.3)\                        clinical criteria, subtype not reported                             E. coli DSM17252 (1.5-4.5×10^7^ c.f.u./ml) 0.75 ml drops t.i.d. for 1 week, then 1.5 ml t.i.d. for weeks 2-8                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     4
                                                                  18-70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adverse events                                                                                                                      

  Williams *et al*.\[[@ref51]\] (2009)              UK            52 (86.5)\                         RomeII, subtype not reported                                        Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Overall IBS symptom scores\                                                                                                         4
                                                                  Unclear                                                                                                One capsule containing L. acidophilus CUL- 60 NCIMB 30157 and CUL-21 NCIMB 30156, B. bifidum CUL-20 NCIMB 30153, and B. lactis CUL-34 NCIMB 30172 (2.5×10^10^ c.f.u./capsule) o.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                         Bloating scores\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Flatulence scores\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Quality of life scores                                                                                                              

  Hong *et al*.\[[@ref38]\] (2009)                  Korea         70 (32.9)\                         RomeIII, 45.7% IBS-D, 20% IBS-C, 8.5% IBS-M, 25.8% Unclassified     Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     5
                                                                  19-75                                                                                                  One sachet containing B. bifidum BGN4, B. lactis AD011, L. acidophilus AD031, and L. casei IBS041 (20 billion bacteria/sachet) b.i.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                      Adverse events                                                                                                                      

  Simren *et al*.\[[@ref42]\] (2010)                Sweden        74 (70.3)\                         RomeII, 35.1% IBS-D, 14.9% IBS-C, 50% IBS-M                         Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms\                                                                                                     5
                                                                  18-70                                                                                                  Fermented milk (200 ml) containing L. paracasei ssp paracasei F19, L. acidophilus La5, and B. lactis Bb12 (5×10^7^ c.f.u./ml) b.i.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                       Abdominal pain scores\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Bloating scores\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Flatulence scores                                                                                                                   

  Guglielmetti *et al*.\[[@ref36]\] (2011)          Germany       122 (67.2)\                        RomeIII, 21.3% IBS-D, 19.7% IBS-C, 59% IBS-M                        Bifidobacterium                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Relief of overall IBS symptoms, Abdominal pain scores, Bloating scores, Flatulence scores, adverse events                           5
                                                                  18-68                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ducrotte *et al*.\[[@ref44]\] (2012)              France        214 (29.4)\                        RomeIII, subtype not reported                                       One capsule containing L. plantarum LP299V DSM 9843 (10 billion c.f.u./capsule) o.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                       Relief of overall IBS symptoms\                                                                                                     5
                                                                  18-70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Overall IBS symptom scores                                                                                                          

  Cui *et al*.\[[@ref34]\] (2012)                   China         60 (70)\                           RomeIII, 48.3% IBS-D, 30% IBS-C, 11.7% IBS-M, 10% Unclassified      Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of abdominal pain                                                                                                            3
                                                                  Unclear                                                                                                Two capsules containing B. longum and L. acidophilus t.i.d. for 4 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Kruis *et al*.\[[@ref24]\] (2012)                 Germany       120 (76.7)\                        RomeII, subtype not reported                                        One capsule containing E. coli Nissle 1917 (2.5-25×10^9^ c.f.u./capsule) o.d. for 4 days then b.i.d. for 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                      Relief of overall IBS symptoms\                                                                                                     5
                                                                  18-65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Adverse events                                                                                                                      

  Roberts *et al*.\[[@ref41]\] (2013)               UK            179 (83.2)\                        RomeIII, 100% IBS-C or IBS-M                                        Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms                                                                                                      4
                                                                  18-65                                                                                                  One pot containing B. lactis I-2494 (previously known as DN173 010) (1.25×10^10^ c.f.u./pot), S. thermophilus I-1630 (1.2×10^9^ c.f.u./pot), and L. bulgaricus I-1632 and I-1519 (1.2×10^9^ c.f.u./pot) b.i.d. for 12 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Begtrup *et al*.\[[@ref33]\] (2013)               Denmark       131 (30)\                          RomeIII, 40.5% IBS-D, 19.1% IBS-C, 38.2% IBS-M, 2.2% Unclassified   Combination\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Relief of overall IBS symptoms, Abdominal pain scores, bloating scores, flatulence scores, quality of life scores                   5
                                                                  18-50                                                                                                  Four capsules containing L. paracasei ssp paracasei F19, L. acidophilus La5, and B. lactis Bb12 (1.3×10^10^ c.f.u./capsule) o.d. for 6 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Sisson *et al*.\[[@ref43]\] (2014)                UK            286 (45.1)\                        RomeIII, 37.6% IBS-D,21.5% IBS-C, 35.5% IBS-M.5.4% Unclassified     Combinationsuspension of barley extract (1 ml/kg) containing Lactobacillus rhamnosus NCIMB 30174, Lactobacillus plantarum NCIMB 30173, Lactobacillus acidophilus NCIMB 30175 and Enterococcus faecium NCIMB 30176 (1×10^10^ c.f.u./50 ml) o.d. for 12 weeks                                                                                                                                                                                                                                                                            Relief of overall IBS symptoms, Abdominal pain scores, bloating scores, flatulence scores, quality of life scores, adverse events   5
                                                                  18-65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Jafari *et al*.\[[@ref25]\] (2014)                Iran          108 (60.2)\                        RomeIII, subtype not reported                                       Combinationone capsule containing Bifidobacterium animalis subsp. lactisBB-12®, Lactobacillus acidophilus LA-5®, Lactobacillus delbrueckii subsp. bulgaricus LBY-27, Streptococcus thermophilus STY-31 (4×10^8^ c.f.u./capsule) b.i.d. for 4 weeks                                                                                                                                                                                                                                                                                     Relief of overall IBS symptoms                                                                                                      5
                                                                  20-70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Ludidi *et al*.\[[@ref26]\] (2014)                Netherlands   40 (67.5)\                         RomeIII, 42.5% IBS-D, 10%\                                          Combinationone sachet containing Bifidobacterium lactis W52, Lactobacillus casei W56, Lactobacillus salivarius W57, Lactococcus lactis W58, Lactobacillus acidophilus NCFM, and Lactobacillus rhamnosus W71 (5×109 c.f.u./sachet) o.d. for 6 weeks                                                                                                                                                                                                                                                                                     Relief of overall IBS symptoms\                                                                                                     4
                                                                  18-65                              IBS-C, 30%\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Abdominal pain scores\                                                                                                              
                                                                                                     IBS-M, 17.5% Unclassified                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Bloating scores                                                                                                                     

  Wong *et al*.\[[@ref47]\] (2015)                  Singapore     42 (45.2)\                         RomeIII, subtype not reported                                       Combinationfour capsules containing VSL\#3 (225 billion bacteria/capsule) b.i.d. for 6 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                           Overall IBS symptom scores\                                                                                                         4
                                                                  20-76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Bloating scores                                                                                                                     

  Pineton de Chambrun *et al*.\[[@ref29]\] (2015)   France        200 (20)\                          RomeIII, 28.5% IBS-D, 46.9% IBS-C, 24.6% IBS-M                      one capsule containing S. cerevisiae CNCM I-3856 (4×10^9^ c.f.u./capsule) o.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                             Relief of overall IBS symptoms\                                                                                                     3
                                                                  18-75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Overall IBS symptom scores\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Adverse events                                                                                                                      

  Mezzasalma *et al*.\[[@ref28]\] (2016)            Italy         157 (not reported)\                RomeIII, 100% IBS: C                                                Combination one capsule containing L. acidophilus, L. reuteri, L. plantarum, L. rhamnosus, and B. animalis subsp. lactis (1.5×10^10^ c.f.u./capsule) o.d. for 2 months                                                                                                                                                                                                                                                                                                                                                                 Relief of overall IBS symptoms\                                                                                                     3
                                                                  18-65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Flatulence scores\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Quality of life scores                                                                                                              

  Lyra *et al*.\[[@ref27]\] (2016)                  Finland       391 (74.7)\                        RomeIII, 38.9% IBS-D, 16.6% IBS-C, 44% IBS-M, 0.5% Unclassified     one capsule containing L. acidophilus NCFM (ATCC 700396) (low dose: 1×109 c.f.u./capsule, high dose: 1×10^10^ c.f.u./capsule) o.d. for 12 weeks                                                                                                                                                                                                                                                                                                                                                                                        Relief of overall IBS symptoms, abdominal pain scores, flatulence scores, quality of life scores, adverse events                    3
                                                                  18-65                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hod *et al*.\[[@ref37]\] (2017)                   Isreal        107 (not reported)\                RomeIII, 100% IBS-D                                                 Combinationone capsule c\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Relief of overall IBS symptoms                                                                                                      4
                                                                  18-70                                                                                                  Lactobacillus rhamnosus LR5 (3×10^9^ CFU/capsule), L. casei LC5 (2×10^9^ CFU/capsule), L. paracasei LPC5 (1×10^9^ CFU/capsule), L. plantarum LP3 (1×10^9^ CFU/capsule), L. acidophilus LA1 (5×109^9^ CFU/capsule), Bifidobacterium bifi- dum BF3 (4×10^9^ CFU/capsule), B. longum BG7 (1×10^9^ CFU/capsule), B. breve BR3 (2×10^9^ CFU/capsule), B. infantis BT1 (1×10^9^ CFU/capsule), Streptococcus thermophilus ST3 (2×10^9^ CFU/capsule), L. bulgaricus LG1, and Lactococcus lactis SL6 (3×10^9^ CFU/capsule) b.i.d. for 8 weeks                                                                                                                                       

  Ishaque, S. M *et al*.\[[@ref49]\] (2018)         Bangladesh    360 (21.9)\                        RomeIII, 100% IBS-D                                                 Combination two capsules containing Bacillus subtilis PXN 21, Bifidobacterium spp. (B. bifidum PXN 23, B. breve PXN 25, B. infantis PXN 27, B. longum PXN 30), Lactobacillus spp. (L. acidophilus PXN 35, L. delbrueckii spp. Bulgaricus PXN39, L. casei PXN 37, L. plantarum PXN 47, L. rhamnosus PXN 54, L.helveticus PXN 45, L. salivarius PXN 57), Lactococcus lactis PXN 63, and Streptococcus thermophilus PXN 66 (2×10^9^ c.f.u./capsule) b.i.d. for 16 weeks                                                                   Abdominal pain scores\                                                                                                              3
                                                                  18-55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Bloating scores\                                                                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Flatulence scores\                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Quality of life scores                                                                                                              

  Shin *et al*.\[[@ref30]\] (2018)                  Korea         51 (56.9)\                         RomeIII, 100% IBS:D                                                 two capsules containing L. gasseri BNR17 (1×10^10^ c.f.u./day) b.i.d. for 8 weeks                                                                                                                                                                                                                                                                                                                                                                                                                                                      Relief of overall IBS symptoms                                                                                                      4
                                                                  20-55                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
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Combination: denotes a mixture of probiotics; c.f.u=Colony-forming units; IBS=Irritable bowel syndrome; o.d.=Once daly.

Risk of bias {#sec2-11}
------------

We judged the risk of bias in the included trials \[[Figure 2](#F2){ref-type="fig"}\]. Sixteen trials described the method of randomization used. Sixteen trials assessed whether adequate concealment of allocation procedure was used, and 24 trials reported methods for blinding participants. Twenty trials described intention-to-treat analyses (ITT) and reported follow-up data. Selective reporting was not found. Therefore, all of the included trials were determined to have a moderate risk of bias. The quality of studies was generally good, with 22 (75.9%) studies scoring at least 4 out of 5 on the Jadad scale \[[Table 2](#T2){ref-type="table"}\].

![Risk of bias of the included studies. Green, low risk; yellow, unclear; red, high risk](SJG-26-66-g002){#F2}

Sensitivity analysis {#sec2-12}
--------------------

The influence of a single study on the overall meta-analysis estimate was investigated by removing one study at a time, and the result showed no significant difference, which indicated our results were statistically reliable.

Main Outcomes and Measures {#sec2-13}
--------------------------

### Efficacy of probiotics in the treatment of IBS: effect on symptom relief {#sec3-10}

Subgroup analysis was performed by different species and strains. Finally, there were 22 RCTs comparing probiotics with placebo for the treatment of IBS,\[[@ref24][@ref25][@ref26][@ref27][@ref28][@ref29][@ref30][@ref31][@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43][@ref44][@ref45]\] evaluating 3144 patients, which gave outcomes as a dichotomous variable \[[Figure 3](#F3){ref-type="fig"}\]. The RR of IBS symptoms improving after treatment with probiotics vs. placebo was 1.50 (95% CI 1.23--1.83), with statistically significant heterogeneity detected between studies (I^2^ = 68%, *P* \< 0.01; [Figure 3](#F3){ref-type="fig"}), There was statistically significant asymmetry detected in the funnel plot (Egger test, *P* = 0.04), to suggest publication bias or other small study effects. The NNT with probiotics was 5 (95% CI 3--8.7).

![Forest plot of randomized controlled trials of probiotics vs placebo in irritable bowel syndrome: effect on symptom relief](SJG-26-66-g003){#F3}

Combination probiotics were assessed in 12 RCTs,\[[@ref25][@ref26][@ref28][@ref33][@ref34][@ref37][@ref38][@ref39][@ref40][@ref41][@ref42][@ref43]\] containing 1240 patients, with a significant effect on symptoms (RR = 1.47; 95% CI 1.13--1.92; [Figure 3](#F3){ref-type="fig"}), but with significant heterogeneity between studies (I^2^ = 68%, P\< 0.01), and asymmetry was not detected in the funnel plot (Egger test, P= 0.78). The NNT with combination probiotics was 6 (95% CI 4.5--8.7).

Lactobacillus was used in five trials (802 patients),\[[@ref27][@ref30][@ref31][@ref35][@ref44]\] with no clear benefit detected over placebo (RR = 1.67; 95% CI 0.87-3.19; [Figure 3](#F3){ref-type="fig"}), again with significant heterogeneity between studies (I^2^ = 86%, P\< 0.01). Bifidobacterium was studied in two RCTs (484 patients),\[[@ref32][@ref36]\] with no benefit over placebo (RR = 1.70; 95% CI 0.73-3.98; [Figure 3](#F3){ref-type="fig"}). E. coli was assessed in two trials (418 patients),\[[@ref24][@ref45]\] with little or no benefit detected compared with placebo (RR = 2.05; 95% CI 0.59-7.08; [Figure 3](#F3){ref-type="fig"}). Finally, Saccharomyces was used in one trial recruiting 100 patients,\[[@ref29]\] and had little or no beneficial effect on IBS symptoms compared with placebo (RR = 1.23; 95% CI 0.92--1.63; [Figure 3](#F3){ref-type="fig"}).

### Efficacy of probiotics in the treatment of IBS: effect on overall IBS and abdominal pain symptom scores {#sec3-11}

There were 18 separate trials,\[[@ref26][@ref27][@ref29][@ref32][@ref33][@ref35][@ref36][@ref39][@ref40][@ref42][@ref43][@ref44][@ref46][@ref47][@ref48][@ref49][@ref50][@ref51]\] making 20 comparisons, containing 2766 patients that reported effect of probiotics on overall IBS or abdominal pain scores \[[Figure 4](#F4){ref-type="fig"}\]. There was a statistically significant effect of probiotics in reducing overall IBS symptoms or abdominal pain (SMD = -0.31; 95% -0.45 to -0.17) with significant heterogeneity (I^2^ = 66%, P\< 0.01; [Figure 4](#F4){ref-type="fig"}). There was no significant asymmetry detected in the funnel plot (Egger test, P= 0.84), to suggest no publication bias or other small study effects. There were three trials (743 patients) that evaluated Lactobacillus,\[[@ref27][@ref44][@ref50]\] and three trials (511 patients) that investigated Bifidobacterium,\[[@ref32][@ref36][@ref50]\] and neither were statistically significantly more efficacious than placebo \[[Figure 4](#F4){ref-type="fig"}\], although there was a trend towards a benefit for the latter (SMD = -0.46; 95% CI -0.92 to 0, P= 0.05).

![Forest plot of randomized controlled trials of probiotics vs placebo in irritable bowel syndrome: effect on overall IBS or abdominal pain scores](SJG-26-66-g004){#F4}

There were 12 trials,\[[@ref26][@ref33][@ref35][@ref39][@ref40][@ref42][@ref43][@ref46][@ref47][@ref48][@ref49][@ref51]\] evaluating 1343 patients, using combinations of probiotics that did suggest a significant improvement in overall IBS symptoms score with active treatment (SMD = -0.35; 95% CI -0.57 to -0.13; [Figure 4](#F4){ref-type="fig"}), with significant heterogeneity between study results (I^2^ = 68%, P\< 0.01). Asymmetry was also not detected in the funnel plot (Egger test, P= 0.82).

### Efficacy of probiotics in the treatment of IBS: effect on individual symptom scores {#sec3-12}

There were 15 separate trials,\[[@ref26][@ref27][@ref32][@ref33][@ref36][@ref39][@ref40][@ref42][@ref43][@ref46][@ref47][@ref48][@ref49][@ref50][@ref51]\] making 17 comparisons, and containing 2283 patients, which reported the effect of probiotics on bloating symptom scores. Overall, there was little reduction in bloating scores with probiotics (SMD = -0.20; 95% CI -0.38 to -0.01), with significant heterogeneity between individual study results (I^2^ = 76%, P\< 0.01)

Three trials reported continuous data for the effect of probiotics on flatulence symptom scores in 407 patients,\[[@ref32][@ref40][@ref46]\] with a significant benefit over placebo (SMD = -0.27; 95% CI -0.65 to 0.11).

Finally, five RCTs reported the effect of probiotics on quality of life (Qol) in 856 patients.\[[@ref28][@ref33][@ref43][@ref49][@ref51]\] There was no apparent benefit detected for probiotics (SMD = -0.07; 95% CI -0.74 to 0.6).

### Adverse events with probiotics {#sec3-13}

Total adverse events were reported by 8 RCTs, containing 1654 patients.\[[@ref24][@ref27][@ref29][@ref36][@ref38][@ref43][@ref45][@ref48]\] Overall, 323 (35%) of 923 patients allocated to probiotics experienced any adverse event, compared with 245 (33.5%) of 731 assigned to placebo. The RR of experiencing any adverse event was not significantly higher with probiotics (1.05; 95% CI 0.85--1.31), but there was significant heterogeneity between studies (I^2^ = 56%, P= 0.03).

DISCUSSION {#sec1-4}
==========

Probiotics have been used to prevent, mitigate or treat specific diseases for years. A multitude of clinical trials have investigated the use of probiotics for diseases ranging from necrotizing colitis in premature infants to hypertension in adults.\[[@ref52][@ref53]\] Although probiotics have also been used clinically to improve the symptoms of IBS for a long time, the precise efficacy of probiotics in IBS is largely unknown. As probiotics have different strains and species, there is no definite conclusion as to which strain and species are more effective. Probiotics have been used safely in foods and dairy products for over a hundred years. However, safety outcomes are inconsistently reported in published clinical trials.\[[@ref54]\] In the current study, we assessed the efficacy and safety of probiotics in IBS, and we detected the effect of different strains and species of probiotics by subgroup analysis.

The key finding of our review is that particular combinations of probiotics, appear to have beneficial effects in IBS in terms of effect on overall IBS symptoms and abdominal pain. However, for specific species and strains of probiotics, we could not find sufficient evidence to support their effectiveness. In addition, on account of the existence of significant heterogeneity between studies, and evidence of publication bias in some analyses, it is difficult to draw definitive conclusions about the efficacy and safety of probiotics. In this study, Lactobacillus, E. coli and Saccharomyces showed little or no beneficial effect and there was a trend towards a beneficial effect of Bifidobacterium, in terms of improvement of overall IBS symptoms and abdominal pain scores. Probiotics may have little beneficial effect on bloating scores, and if at all, then the particular strain or species remains unclear.

A previous study showed better beneficial effects of combination probiotics than individual probiotics in IBS, which is a similar conclusion to ours after incorporating two new studies.\[[@ref55]\] However, after pooling one new study, our analysis showed that probiotics have no beneficial effect on flatulence, a conclusion different from the previous study. The possible reason for this different outcome that studies included in our current analysis are not quite sufficient, and the two new studies may have an effect on the pooled result. However, there is adequate evidence that combination probiotics provide efficacy in IBS.

In the current systematic review and meta-analysis, eight studies reported adverse events including abdominal pain, diarrhea, constipation, nausea, and skin reactions, which were generally tolerated. Besides, the appearance of adverse events was not significantly different for disparate interventions, which indicated that probiotics were secure for IBS patients.

The strength of this systematic review and meta-analysis is that we performed a subgroup analysis to detect the effectiveness of various strains and species of probiotics and assessed the safety of probiotics in IBS. There are limitations to this analysis, which arise from the nature of the studies available for synthesis. The risk of bias of many of the trials that we identified was unclear, and there was evidence of heterogeneity between RCTs in some of our analyses, although there was no evidence of publication bias among trials of probiotics in IBS. In addition, although we attempted to uncover the species and strains of probiotics which were effective, there were a limited number of trials in some of these subgroup analyses, meaning that we may have had insufficient power to detect any meaningful difference in effect. Therefore, it remains unclear whether a particular combination of probiotics is more likely to be effective, or whether there is a particular IBS subtype that is more likely to benefit. Finally, individual strains of probiotics may have different effects, and pooling all studies from a given species may obscure the beneficial effects of individual strains within that species, although if there were more evaluable studies examining each of these individual strains then we would perhaps be able to make judgments about their efficacy, and compare the efficacy between strains.

In summary, this meta-analysis shows that probiotics can significantly improve the overall symptoms of IBS and abdominal pain scores. Combinations of probiotics appears to show a significant improvement in overall IBS scores. However, as there were various combinations of probiotics, we could not ascertain which combination of probiotics is more effective. Different doses may affect the efficacy of probiotics, therefore, further research should focus on combination probiotics with a fixed dose.

CONCLUSION {#sec1-5}
==========

The current review has demonstrated that specific combinations of probiotics seem to have beneficial effects on overall IBS symptoms and abdominal pain. However, due to the limited combinations of probiotics and large heterogeneity in the included studies, it is unclear how precisely probiotics can facilitate the relief of IBS symptoms and which particular combination can be the best. Therefore, future research should pay more attention to detect the effect of different probiotic combinations on IBS.
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